Products
Catridecacog is used as a powder and solvent for the preparation of a solution for injection (NovoThirteen). It was approved in many countries in 2012.
Structure and properties
Catridecacog is the recombinant blood clotting factor XIII A subunit and is equivalent to the human FXIII A subunit.
Effects
Catridecacog (ATC B02BD11) is effective against blood clotting disorders.
Indications
For prevention of bleeding in patients with congenital factor XIII A subunit deficiency and relevant bleeding risk.
Dosage
According to the SmPC. The drug is injected intravenously.
Contraindications
Catridecacog is contraindicated in hypersensitivity, congenital factor XIII B subunit deficiency, and severe hepatic insufficiency. For complete precautions, see the drug label.
Interactions
There are no known drug-drug interactions.
Adverse effects
The most common possible adverse effects include non-neutralizing antibodies, leukopenia, neutropenia, headache, pain in the limbs, pain at the injection site
